GLP-1 & GIP Weight Loss
Semaglutide for Weight Loss: GLP-1 & GIP and Medication Programs
Welcome to Semaglutide for Weight Loss, a national leader in physician-supervised telemedicine. We provide safe, effective, and evidence-based weight management protocols using advanced GLP-1 and GIP receptor agonists. Our comprehensive telehealth platform brings specialized, board-certified medical guidance directly to your home.
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are metabolic hormones naturally produced by your body. Modern medical formulations mimic these hormones to optimize insulin secretion, delay gastric emptying, and signal fullness directly to your brain. Below is an educational overview of the premier medications we prescribe, including their benefits, scientific research, and safety profiles.
Therapies
Semaglutide: The Gold Standard in Weight Loss
Semaglutide is a selective, long-acting GLP-1 receptor agonist that has revolutionized chronic weight management.
- Primary Benefits: Substantial reductions in body weight, decreased food cravings, eliminated “food noise,” and improved cardiovascular risk factors.
- The Science: Landmark clinical findings published in The New England Journal of Medicine (NEJM) show that patients using semaglutide achieved an average weight loss of approximately 15% of their initial body weight over 68 weeks.
- Dosing Best Practices: Administered via a tiny subcutaneous injection once weekly. Protocols follow a strict titration schedule, beginning at 0.25 mg and scaling up every four weeks to ensure maximum tolerability.
- Potential Side Effects: Nausea, vomiting, diarrhea, constipation, and mild abdominal discomfort.
Tirzepatide: Dual GLP-1 & GIP Action
Tirzepatide is a first-in-class, single-molecule dual agonist that targets both GLP-1 and GIP metabolic receptors for unparalleled efficacy.
- Primary Benefits: Superior weight reduction, enhanced blood glucose control, optimized fat tissue breakdown, and comprehensive metabolic restoration.
- The Science: Extensive data reviewed by the U.S. Food and Drug Administration (FDA) confirms that tirzepatide’s dual-action mechanism leads to even greater weight reductions than selective GLP-1 therapy alone, with many patients achieving over 20% total body weight loss.
- Dosing Best Practices: Injected subcutaneously once weekly. Therapy starts at a low dose of 2.5 mg and increases progressively in 2.5 mg increments every month based on personal clinical results.
- Potential Side Effects: Heartburn, decreased appetite, nausea, mild fatigue, or localized redness at the injection site.
Liraglutide: Daily Metabolic Control
Liraglutide is a proven, shorter-acting GLP-1 receptor agonist that provides excellent day-to-day metabolic flexibility.
- Primary Benefits: Consistent appetite suppression, improved glycemic control, and a long-standing clinical safety track record spanning more than a decade.
- The Science: Long-term safety guidelines and clinical archives maintained by the National Institutes of Health (NIH) document liraglutide’s capability to help patients sustain meaningful weight loss while substantially lowering the risk of developing type 2 diabetes.
- Dosing Best Practices: Administered as a once-daily subcutaneous injection. The protocol titrates up weekly from an initial 0.6 mg dose to a target maintenance dose of 3.0 mg.
- Potential Side Effects: Transient nausea, mild headaches, low blood sugar (hypoglycemia) when combined with other metabolic therapies, or constipation.
How to Get Started
Ready to safely regain control of your health under dedicated medical supervision? Achieving lasting weight loss and metabolic vitality requires a personalized plan tailored specifically to your biology.
To get started, simply complete our online medical intake form to securely provide your health background to our team. Once submitted, you can immediately book a free consultation with one of our licensed telemedicine physicians to determine the optimal medication protocol for your goals.